Table 1.
Description of U.S. MenB-4C reports received by the Vaccine Adverse Event Reporting System (VAERS) from January 23, 2015 through December 31, 2018.
| Reports; n (%)$ | ||||
|---|---|---|---|---|
| All | Non-serious | Serious non-fatal¥ | MenB-4C only | |
| Total reportse | 1,867 (100) | 1,785 (100) | 80 (100) | 1,122 (100) |
| Age group (years) | ||||
| ≤9 | 13 (1) | 12 (1) | 1 (1) | 8 (1) |
| 10–17 | 832 (45) | 795 (45) | 36 (45) | 373 (33) |
| 18–25 | 667 (36) | 642 (36) | 25 (31) | 450 (40) |
| ≥26 | 47 (3) | 43 (2) | 4 (5) | 25 (2) |
| Unknown | 308 (16) | 293 (16) | 14 (18) | 266 (24) |
| Sex | ||||
| Female | 1,094 (59) | 1,053 (59) | 40 (50) | 680 (61) |
| Male | 609 (33) | 572 (32) | 36 (45) | 300 (27) |
| Unknown | 164 (9) | 160 (9) | 4 (5) | 142 (13) |
| Adverse event onset (days) | ||||
| 0 | 866 (46) | 830 (46) | 36 (45) | 451 (40) |
| 1 | 327 (18) | 319 (18) | 8 (10) | 181 (16) |
| ≥2 | 199 (11) | 177 (10) | 22 (28) | 107 (10) |
| Unknown | 475 (25) | 459 (26) | 14 (18) | 383 (34) |
| Year received in VAERS | ||||
| 2015 | 50 (3) | 45 (3) | 5 (6) | 33 (3) |
| 2016 | 559 (30) | 533 (30) | 26 (33) | 346 (31) |
| 2017 | 595 (32) | 569 (32) | 24 (30) | 343 (31) |
| 2018 | 663 (36) | 638 (36) | 25 (31) | 400 (36) |
Abbreviations: MenB-4C, Four-component meningococcal group B vaccine; Tdap, Tetanus-diphtheria-acellular pertussis.
$
Percentages may not add up to 100% due to rounding.
¥
Excludes death reports (n = 2).
e
Based on information included in initial reports